Journal Mobile Options
Table of Contents
Vol. 25, No. 3, 2009
Issue release date: September 2009
Fetal Diagn Ther 2009;25:320–327
(DOI:10.1159/000235878)

Maternal Serum Activin A at 11–13 Weeks of Gestation in Hypertensive Disorders of Pregnancy

Akolekar R. · Etchegaray A. · Zhou Y. · Maiz N. · Nicolaides K.H.
Harris Birthright Research Centre for Fetal Medicine, King’s College Hospital, London, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: To investigate whether the maternal serum concentration of activin A at 11–13 weeks of gestation in pregnancies that subsequently develop hypertensive disorders is different from those with a normal outcome and to examine whether any possible differences are related to uterine artery pulsatility index (PI), serum pregnancy-associated plasma protein A (PAPP-A) and serum tumor necrosis factor-α receptor-1 (TNF-R1). Material and Methods: Serum activin A, TNF-R1, PAPP-A and uterine artery PI were determined in a case-control study of 126 cases that developed preeclampsia, 88 that developed gestational hypertension and 214 controls. Results: In preeclampsia, compared to controls, uterine artery PI, serum activin A and serum TNF-R1 were higher and serum PAPP-A was lower. In gestational hypertension, compared to controls, serum activin A was higher but uterine artery PI, serum PAPP-A and serum TNF-R1 were not significantly different. There were no significant associations between serum activin A and either uterine artery PI or serum TNF-R1 in either the hypertensive groups or the controls. Discussion: The data do not support the hypothesis linking activin A with impaired trophoblastic invasion of the maternal spiral arteries, placental hypoxia and the release of cytokines which in turn cause endothelial dysfunction and the development of the clinical symptoms of the disease.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Petraglia F: Inhibin, activin and follistatin in the human placenta – a new family of regulatory proteins. Placenta 1997;18:3–8.
  2. Florio P, Cobellis L, Luisi S, Ciarmela P, Severi FM, Bocchi C, Petraglia F: Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol Cell Endocrinol 2001;180:123–130.
  3. Muttukrishna S, Child TJ, Groome NP, Ledger WL: Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod 1997;12:1089–1093.
  4. Petraglia F, De Vita D, Gallinelli A, Aguzzoli L, Genazzani AR, Romero R, Woodruff TK: Abnormal concentration of maternal serum activin-A in gestational diseases. J Clin Endocrinol Metab 1995;80:558–561.
  5. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL: Activin A and inhibin A as possible endocrine markers for preeclampsia. Lancet 1997;349:1285–1288.
  6. Silver HM, Lambert-Messerlian GM, Star JA, Hogan J, Canick JA: Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Am J Obstet Gynecol 1999;180:1131–1137.
  7. D’Antona D, Reis FM, Benedetto C, Evans LW, Groome NP, de Kretser DM, Wallace EM, Petraglia F: Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders. J Endocrinol 2000;165:157–162.
  8. Yair D, Eshed-Englender T, Kupferminc MJ, Geva E, Frenkel J, Sherman D: Serum levels of inhibin B, unlike inhibin A and activin A, are not altered in women with preeclampsia. Am J Reprod Immunol 2001;45:180–187.
  9. Manuelpillai U, Schneider-Kolsky M, Dole A, Wallace EM: Activin A and activin receptors in gestational tissue from preeclamptic pregnancies. J Endocrinol 2001;171:57–64.
  10. Keelan JA, Taylor R, Schellenberg JC, Groome NP, Mitchell MD, North RA: Serum activin A, inhibin A, and follistatin concentrations in preeclampsia or small for gestational age pregnancies. Obstet Gynecol 2002;99:267–274.
  11. Florio P, Ciarmela P, Luisi S, Palumbo MA, Lambert-Messerlian G, Severi FM, Petraglia F: Pre-eclampsia with fetal growth restriction: placental and serum activin A and inhibin A levels. Gynecol Endocrinol 2002;16:365–372.
  12. Bersinger NA, Smárason AK, Muttukrishna S, Groome NP, Redman CW: Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy 2003;22:45–55.
  13. Diesch CH, Holzgreve W, Hahn S, Zhong XY: Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn 2006;26:1267–1270.
  14. Grobman WA, Wang EY: Serum levels of activin A and inhibin A and the subsequent development of preeclampsia. Obstet Gynecol 2000;96:390–394.
  15. Davidson EJ, Riley SC, Roberts SA, Shearing CH, Groome NP, Martin CW: Maternal serum activin, inhibin, human chorionic gonadotrophin and alpha-fetoprotein as second trimester predictors of pre-eclampsia. BJOG 2003;110:46–52.
  16. Florio P, Reis FM, Pezzani I, Luisi S, Severi FM, Petraglia F: The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2003;21:165–169.
  17. Ong CY, Liao AW, Munim S, Spencer K, Nicolaides KH: First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction. J Matern Fetal Neonatal Med 2004;15:176–180.
  18. Ay E, Kavak ZN, Elter K, Gokaslan H, Pekin T: Screening for pre-eclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. Aust N Z J Obstet Gynaecol 2005;45:283–288.
  19. Madazli R, Kuseyrioglu B, Uzun H, Uludag S, Ocak V: Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2005;89:251–257.
  20. Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH: Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks’ gestation. Ultrasound Obstet Gynecol 2006;27:658–663.
  21. Banzola I, Farina A, Concu M, Sekizawa A, Purwosunu Y, Strada I, Arcelli D, Simonazzi G, Caramelli E, Rizzo N: Performance of a panel of maternal serum markers in predicting preeclampsia at 11–15 weeks’ gestation. Prenat Diagn 2007;27:1005–1010.
  22. Spencer K, Cowans NJ, Nicolaides KH: Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:622–626.
  23. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for- gestational age infants. Br J Obstet Gynaecol 1986;93:1049–1059.
  24. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A: Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991;98:648–655.
  25. Roberts JM, Redman CW: Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447–1451.
  26. Redman CWG: Pre-eclampsia and the placenta. Placenta 1991;12:301–308.
  27. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA: Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001;38:718–722.
  28. Bearfield C, Jauniaux E, Groome N, Sargent IL, Muttukrishna S: The effect and secretion of inhibin A, activin A and follistatin on first trimester trophoblasts in vitro. Eur J Endocrinol 2005;152:909–916.
  29. Muttukrishna S, Hyett J, Paine M, Moodley J, Groome N, Rodeck C: Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol (Oxf) 2006;64:469–473.
  30. Mohan A, Asselin J, Sargent IL, Groome NP, Muttukrishna S: Effect of cytokines and growth factors on the secretion of inhibin A, activin A and follistatin by term placental villous trophoblasts in culture. Eur J Endocrinol 2001;145:505–511.
  31. Leal AM, Poon LCY, Frisova V, Veduta A, Nicolaides KH: First-trimester maternal serum tumor necrosis factor receptor-1 and preeclampsia. Ultrasound Obstet Gynecol 2009;33:135–141.
  32. Tannetta DS, Muttukrishna S, Groome NP, Redman CW, Sargent IL: Endothelial cells and peripheral blood mononuclear cells are a potential source of extraplacental activin a in preeclampsia. J Clin Endocrinol Metab 2003;88:5995–6001.
  33. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH: Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007;30:742–749.
  34. Poon LCY, Maiz N, Valencia C, Plasencia W, Nicolaides KH: First-trimester maternal serum PAPP-A and preeclampsia. Ultrasound Obstet Gynecol 2009;33:23–33.
  35. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343–346.
  36. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH: Screening for trisomy 21 by maternal age, fetal NT, free beta-hCG and PAPP-A. Ultrasound Obstet Gynecol 2008;31:618–624.
  37. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV.
  38. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493–502.
  39. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR 3rd, Conover CA: The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999;96:3149–3153.
  40. Bonno M, Oxvig C, Kephart GM, Wagner JM, Kristensen T, Sottrup-Jensen L, Gleich GJ: Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. Lab Invest 1994;71:560–566.
  41. Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC: Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod 1999;14(suppl 2):90–96.

    External Resources

  42. Petraglia F, Aguzzoli L, Gallinelli A, Florio P, Zonca M, Benedetto C, Woodruff K: Hypertension in pregnancy: changes in activin A maternal serum concentration. Placenta 1995;16:447–454.
  43. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, Ledger W, Groome N, Redman CW: Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 2000;15:1640–1645.
  44. Khalil A, Jauniaux E, Harrington K, Muttukrishna S: Placental production and maternal serum and urine levels of inhibin A and activin A are modified by antihypertensive therapy in hypertensive disorders of pregnancy. Clin Endocrinol (Oxf) 2009; 70:924–931.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50